Lung Disease News |
Teva Announces FDA Acceptance of Reslizumab For Asthma
Lung Disease News Reslizumab is being developed as treatment of inadequately controlled asthma in adults and young people who have increased blood eosinophils, despite being under treatment with an inhaled corticosteroid (ICS) drug regimen. “Despite currently available … FDA to review Teva asthma biologic FDA will review Teva's asthma biologic reslizumab Stock Update (NYSE:TEVA): Teva Pharmaceuticals Industries Ltd (ADR … |
View full post on asthma – Google News